| abstract |
The invention relates to a fusion protein mutant capable of directionally killing tumour cells, which consists of an orienting part and an effect part, wherein the orienting part consists of gonadotropin releasing hormone (GnRH), the effect part consists of cytotoxin, and the fusion protein mutant has the characteristics that the tumour cells excessively expressing GnRH receptors can be directionally reached and killed. |